Valneva SE's stock surged 7.55% during intraday trading on Wednesday following the release of positive final data from a mid-stage study of its Lyme disease vaccine candidate, VLA15, developed in collaboration with Pfizer. The results showed sustained antibody levels across all six Lyme disease serotypes and age groups, with a favorable safety profile.

The vaccine candidate, VLA15, is the most advanced in development for Lyme disease, with analysts highlighting a high probability of success in late-stage trials. The findings support the potential for yearly vaccinations ahead of Lyme season, addressing a significant unmet medical need. This development positions Valneva as a key player in the biotech space, with the phase 3 trial results expected in the first half of 2026.